The EDV nanocell is a first-in-class cyto-immunotherapy platform targeting the tumor directly and leveraging the patient’s own immune system.








Learn more about EnGeneIC Dream Vector (EDV™) Nanocell platform technology

Abstract accepted  to the Annual Meeting of the American Society of Clinical Oncology 2020

Abstract Demonstrates Promising Early Results from Phase I/IIa study in Patients with Recurrent, Metastatic Pancreatic Cancer.

Publication in prestigious scientific journal, Cancer Cell, highlighting the ability of EDV™ Nanocells to mount dual assault on Cancer Cells

EDV™ Technology Stimulates Both Innate and Adaptive Immune Response and Confers Long-Term Survival

EnGeneIC Novel Oncology-Focused Nanotechnology Featured in InsightsCare

The 10 Most Innovative Healthcare Nanotech Companies to Watch

EnGeneIC Wins Innovation Awards from Australian Financial Review

Named Most Innovative Healthcare Company of 2019 for its Nanocell Platform for Targeted Cyto-Immunotherapy in Cancer Treatment

Winner in Drug Delivery Technology category by Fierce Innovation Awards – Life Sciences Edition 2019